Editorial: TNFRSF agonists: mode of action and therapeutic opportunities

Front Immunol. 2023 Nov 7:14:1328100. doi: 10.3389/fimmu.2023.1328100. eCollection 2023.

Authors

Nataša Obermajer¹, Adam Zwolak², Harald Wajant³

Affiliations

¹ Oncology R&D, Johnson and Johnson Innovative Medicine, Beerse, Belgium.
² Therapeutics Discovery, Johnson and Johnson Innovative Medicine, Spring House, PA, United States.
³ Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.

No abstract available

Keywords: Fcgamma receptor; TNFRSF; agonism; antibody design; co-stimulation; immunostimulation; immunotherapy; signaling/signaling pathways.

Publication types

Editorial

MeSH terms

Receptors, Tumor Necrosis Factor* / agonists

Substances

Receptors, Tumor Necrosis Factor

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.